In a randomized, double-blind, placebo-controlled study, 11 moderately arthritic dogs received placebo or Natreon’s Crominex 3+ twice daily for a period of 150 days. On a monthly basis, each dog was evaluated for arthritis associated pain (overall pain, pain upon limb manipulation and pain after physical exertion) and a full physical exam (body weight, body temperature and heart rate) was conducted. At the same time intervals, serum samples were examined for biomarkers of kidney (BUN and creatinine), liver (bilirubin, ALT and AST) and heart and skeletal muscle (CK) functions.
According to Dr. Sanni Raju, Natreon CEO of Natreon, study findings revealed dogs receiving Crominex 3+ (1000 μg chromium, 15 mg Phyllanthus emblica extract and 15 mg purified Shilajit per day in two divided doses) exhibited a significant (P<0.05) reduction in arthritic pain noted as early as after 90 days with a maximum reduction after 150 days of treatment. Pain level remained the same or slightly increased in the dogs receiving placebo. No significant change occurred in physical parameters or serum biomarkers in dogs on placebo or Crominex 3+, which suggested that Crominex 3+ was well tolerated by arthritic dogs.
The study concluded that Crominex 3+ significantly (P<0.05) ameliorated arthritic pain and improved quality of life without causing any untoward effects in moderately arthritic dogs.
For more information: www.natreoninc.com